Show simple item record

dc.contributor.authorBlakkisrud, Johan
dc.contributor.authorHoltedahl, Jon Erik
dc.contributor.authorLøndalen, Ayca
dc.contributor.authorDahle, Jostein
dc.contributor.authorBach-Gansmo, Tore
dc.contributor.authorHolte, Harald
dc.contributor.authorNygaard, Stine
dc.contributor.authorKolstad, Arne
dc.contributor.authorStokke, Caroline
dc.date.accessioned2019-01-31T14:01:15Z
dc.date.accessioned2019-03-15T10:15:31Z
dc.date.available2019-01-31T14:01:15Z
dc.date.available2019-03-15T10:15:31Z
dc.date.issued2018-08-28
dc.identifier.citationBlakkisrud J, Holtedahl JE, Løndalen AL, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C. Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-Radionuclide conjugate 177Lu-Lilotomab satetraxetan. Journal of Nuclear Medicine. 2018;59(4):704-710en
dc.identifier.issn0161-5505
dc.identifier.issn0161-5505
dc.identifier.issn1535-5667
dc.identifier.urihttps://hdl.handle.net/10642/6779
dc.description.abstract177Lu-lilotomab satetraxetan is a novel antibody radionuclide conjugate (ARC) currently in a phase 1/2a first-in-human dosage escalation trial for patients with relapsed CD37+ indolent non Hodgkin lymphoma (NHL). The aim of this study was to investigate biodistribution and absorbed doses to organs at risk. Methods: A total of seven patients treated with 177Lu-lilotomab satetraxetan were included for dosimetry. Patients were grouped based on two different pre-dosing regimens (with and without pre-dosing with 40 mg lilotomab) and were treated with different levels of activity per body weight (10, 15 and 20 MBq/kg). All patients were pre-treated with rituximab. Serial planar and SPECT/CT-images were used to determine time activity curves and patient specific masses for organs with 177Lu-lilotomab satetraxetan uptake. Doses were calculated with OLINDA/EXM. Results: Organs with distinct uptake of 177Lu-lilotomab satetraxetan, in addition to red bone marrow and tumors, were liver, spleen and kidneys. Largest uptake was found in the spleen, where doses ranged from 1.54 to 3.60 mGy/MBq. The liver received 0.70 to 1.15 mGy/MBq. The kidneys received the lowest dose of the source organs investigated; 0.16 to 0.79 mGy/MBq. No statistical significant differences in soft tissue absorbed doses for the two pre-dosing regimens were found. Whole body (WB) dose ranged from 0.08 to 0.17 mGy/MBq. Conclusion: The biodistribution study for patients treated with 177Lu-lilotomab satetraxetan revealed highest physiological uptake in liver and spleen, besides red marrow. For all dosage levels investigated, doses were found modest when compared to commonly assumed tolerance limits.en
dc.description.sponsorshipThe LYMRIT37-01 study is sponsored by Nordic Nanovector ASA. Johan Blakkisrud is supported by grants from the South-Eastern Norway Regional Health Authority. Harald Holte and Arne Kolstad were both in part supported by grants from the Norwegian Cancer Society.en
dc.language.isoenen
dc.publisherSociety of Nuclear Medicineen
dc.relation.ispartofseriesJournal of Nuclear Medicine;April 1, 2018; Vol. 59, no. 4
dc.rightsThis research was originally published in JNM. Johan Blakkisrud, Jon Erik Holtedahl Ayca Løndalen, Jostein Dahle Tore Bach-Gansmo, Harald Holte, Stine Nygaard, Arne Kolstad, Caroline Stokke. Biodistribution and dosimetry results from a phase 1 trial of 177 Lu-lilotomab satetraxetan antibody-radionuclide-conjugate therapy. J Nucl Med. 2018; vol. 59 no. 4, p. 704-710. © SNMMIen
dc.subjectBiodistributionsen
dc.subjectAntibody radionuclide conjugationsen
dc.subjectNon-Hodgkin’s lymphomaen
dc.subjectInternal dosimetriesen
dc.titleBiodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-Radionuclide conjugate 177Lu-Lilotomab satetraxetanen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2019-01-31T14:01:15Z
dc.description.versionacceptedVersionen
dc.identifier.doihttp://dx.doi.org/10.2967/jnumed.117.195347
dc.identifier.cristin1597582
dc.source.journalJournal of Nuclear Medicine


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record